Outlook Therapeutics Inc

NASDAQ:OTLK   10:06:43 AM EDT
1.52
+0.02 (+1.33%)
Products

Outlook Submits Biologics License Application To U.S. FDA For ONS-5010 As Wet AMD Treatment

Published: 03/31/2022 12:57 GMT
Outlook Therapeutics Inc (OTLK) - Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ons-5010 As a Treatment for Wet Amd.
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ons-5010 As a Treatment for Wet Amd.
Outlook Therapeutics Inc - Ons-5010 / Lytenava™ (bevacizumab-vikg), If Approved, Expected to Receive 12 Years of Marketing Exclusivity.